相关实验视频
Updated: Jun 7, 2025

08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
49.8K
卢比盐可以有效地缓解DSS诱导的性结肠炎的症状
Lichun Zhao1, Wenhao Weng2, Mengyue Ni2
1Guang Xi University of Chinese Medicine, Nanning, China; Guangxi Zhuangyao Pharmaceutical Engineering Technology Research Center, Nanning 530200, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|November 9, 2024
概括
鲁比盐通过减少炎症和改善肠道屏障功能,有效治疗性结肠炎. 它重新平衡肠道微生物群,增加有益的细菌,减少有害的细菌,从而减轻疾病症状.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎,是一种慢性疾病,影响患者的生活质量.
- 目前对IBD的治疗方法有限,需要探索新的治疗药物.
研究的目的:
- 在性结肠炎模型中研究卢比盐的治疗效果.
- 阐明卢比盐对肠道炎症和肠道微生物群的影响的机制.
主要方法:
- 评估炎症标志物和肠道屏障功能,使用Elisa套件,免疫组织化学和qPCR.
- 量化短链脂肪酸 (SCFA) 和分析便基因组学以评估肠道微生物群组成.
- 研究了细菌毒性因子和基因的表达.
主要成果:
- 卢比盐治疗减少了炎症标志物,并增强了肠道屏障的完整性.
- 在治疗后,SCFA水平,特别是酸和黄油酸,都增加了.
- 微生物群分析显示,有益细菌 (乳酸菌,双菌) 的丰富性增加,有害细菌 (肠杆菌,大肠杆菌) 的减少.
- 鲁比盐降低了致病细菌中的毒性因子 (fimH, invA, hilA) 和基因 (acrA, ompR) 的调节.
结论:
- 鲁比盐在性结肠炎中显示出显著的治疗潜力.
- 它的机制涉及调节肠道微生物群,增加有益细菌,减少致病细菌.
- 增强的SCFA生产和加强的肠道屏障有助于缓解性结肠炎症状.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
390
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
390
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Inflammatory Bowel Disease IV: Pharmacological Management
114
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
114

